Blog
RSS FeedPosted by Michael Wonder on 18 Mar 2019
NICE celebrates its 20th anniversary
18 March 2019 - Organisation was founded in April 1999 to improve outcome for health service users ...
Posted by Michael Wonder on 14 Mar 2019
One in four cancer patients wait two months for treatment, as NHS performance hits record low
14 March 2019 - The number of cancer sufferers waiting at least two months for treatment after an urgent referral ...
Posted by Michael Wonder on 14 Mar 2019
An EU wide approach to HTA: an irrelevant development or an opportunity not to be missed?
14 March 2019 - An EU-wide cooperation on HTA has been proposed recently by the European Commission, focusing on relative effectiveness ...
Posted by Michael Wonder on 14 Mar 2019
UK breast cancer patients win early access to Tecentriq/nab-paclitaxel
14 March 2019 - Adults in the UK with PD-L1 positive, unresectable locally advanced or metastatic triple-negative breast cancer have ...
Posted by Michael Wonder on 13 Mar 2019
Cancer patient denied life-prolonging drug as she lives half a mile outside England
13 March 2019 - A seriously ill mum-of-two has spoken of her devastation after being denied a life prolonging cancer drug ...
Posted by Michael Wonder on 13 Mar 2019
Pharma urges politicians to stop no-deal Brexit in today’s vote
13 March 2019 - Pharma has urged politicians to reject a no-deal Brexit in today’s crunch vote, reiterating warnings that ...
Posted by Michael Wonder on 12 Mar 2019
Optimism on Orkambi in England as talks to resume
12 March 2019 - Scotland's deal puts pressure on NHS England and NICE. ...
Posted by Michael Wonder on 12 Mar 2019
NICE u-turn backs use of Darzalex combo for myeloma relapse
12 March 2019 - Myeloma patients in England are set to gain NHS access to a new second-line treatment combination ...
Posted by Michael Wonder on 11 Mar 2019
NICE nod for Almirall's Ilumetri, UCB's Cimzia
11 March 2019 - The NICE has recommended Almirall's Ilumetri and UCB's Cimzia as a treatment options for severe plaque ...
Posted by Michael Wonder on 11 Mar 2019
How a post-Brexit trade deal with the US could make life-saving drugs unaffordable for the NHS
10 March 2019 - The UK is going to be at a distinct disadvantage in this negotiation – desperate for a ...
Posted by Michael Wonder on 11 Mar 2019
Cystic fibrosis breakthrough: vital drug could be made available as early as next month
8 March 2019 - A wonder drug that could dramatically improve the lives of thousands of cystic fibrosis patients may be ...
Posted by Michael Wonder on 11 Mar 2019
NICE provisionally approves Almirall's Ilumetri (tildrakizumab), as a cost effective option for adults with moderate-to-severe plaque psoriasis
8 March 2019 - Final NICE approval is expected in April 2019. ...
Posted by Michael Wonder on 08 Mar 2019
Campaigners call for NHS access to Orkambi as MP inquiry gets underway
8 March 2019 - Patients and campaigners took to the streets in London yesterday demanding NHS access to Vertex’ cystic ...
Posted by Michael Wonder on 08 Mar 2019
High price of cystic fibrosis drug not political, firm's boss tells MPs
8 March 2019 - CEO of company that makes Orkambi denies being ‘political minion’ for Donald Trump. ...
Posted by Michael Wonder on 06 Mar 2019
In UK and Ireland, SMA patients demand reimbursement for Spinraza
6 March 2019 - A drug appraisal committee of Britain’s NICE met in Manchester, England, for the third and final ...